Partnerships and co-selling for B2B SaaS founders for healthcare and life sciences in emerging markets
A founder-first breakdown of partnerships and co-selling — the parts you have to own personally, the parts you can delegate, and the traps that eat the first 18 months. Written for commercial leaders at healthtech, medtech, and life-sciences companies in emerging markets.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in emerging markets. In this market, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint, so the way you install partnerships and co-selling has to be shaped to that reality from day one.
If you are a B2B SaaS founder still under $5m ARR, partnerships and co-selling is not something you delegate on day one. It is using another company's distribution to reach buyers you cannot cost-effectively reach yourself, and until it works you cannot describe your business without hand-waving.
The founder value in partnerships and co-selling is that one great partner is worth ten marketing hires. You bring context no hire can replicate — the reason you started the company, the exact objection you heard on call number seven, the phrase a customer used that finally clicked.
Own the strategy, the first 30 live cycles, and the weekly review. Delegate the tooling, the list building, and the reporting. Founders who invert that order end up hiring around a broken model.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in emerging markets it is compounded by the fact that operating footprint and pricing fit, not brand awareness is what actually gates growth. Partnerships and co-selling is only useful here when it is pointed at both constraints at once.
Instrument sourced and influenced pipeline from partners from day one — even if the number is embarrassing. You cannot debug what you do not measure, and every board meeting after Series A will start with this chart.
The founder trap in partnerships and co-selling is signing MOUs no one operationalises. It always looks reasonable at the time. Write the trap on a sticky note and stick it on your monitor.
The moment to hand off partnerships and co-selling is when you can predict the number two weeks out and defend the assumptions behind it. Not before. VP hires that arrive earlier tend to leave inside 14 months.
Founders who take partnerships and co-selling seriously in year one write category-defining companies in year three. The compounding is that stark.
Concretely for healthcare and life sciences in emerging markets: the healthcare teams that install this get past procurement instead of dying in it, and the teams that install this early own the category before Western vendors even show up. That is the reason it is worth installing partnerships and co-selling deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Partnerships · healthcare · emerging markets — answered
- Does partnerships and co-selling work for healthcare and life sciences in emerging markets?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint. The healthcare teams that install this get past procurement instead of dying in it.
- Should the founder personally run partnerships and co-selling?
- Yes, until you can predict the number two weeks out. Then hand off the ops and keep the strategy.
- When can I hire someone to own partnerships and co-selling?
- When the metric is legible, the operating rhythm is documented, and you would rather work on the next constraint.
- What is the founder-specific mistake with partnerships and co-selling?
- Signing MOUs no one operationalises — usually because the founder wants to move on before the model is proven.
- How much of my week should partnerships and co-selling take as a founder?
- Roughly a third for the first two quarters, dropping to a weekly review once the metric is stable.
- What is the emerging markets-specific pitfall when running partnerships and co-selling for healthcare?
- Importing a playbook that was built for another market. In emerging markets, emerging-market buyers reward patient capital, currency-aware pricing, and a real local operating footprint — the install has to reflect that.
Growth Broker editorial
Filed under partnerships · healthcare · emerging markets